FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

5-0287
0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Responses	s)													
1. Name and Address of Reporting Person* MOOS WALTER H				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						1	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/28/2010							Officer (giv	e title below)	Other	(specify below)	
(Street) SOUTH SAN FRANCISCO, CA 94025-3493				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person				
(Cit	y)	(State)	(Zip)			Ta	ble I	- Non-Deri	vative Securition	es Acquired	l, Disposed	of, or Bene	ficially Owned	1	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year		Execution Date, if any (Month/Day/Year)			8) (A. Securities Acq A) or Disposed of Instr. 3, 4 and 5	of (D) Ow Tra (Ins	Owned Following Re Transaction(s) (Instr. 3 and 4)		d OFO	wnership orm: irect (D) Indirect (In	Nature Indirect eneficial wnership astr. 4)			
Reminder:	Report on a s	separate line for each		Derivati	ive S	Securities	Acq	Persor in this display uired, Disp	s who respon form are not r rs a currently osed of, or Beno onvertible secur	required to valid OME eficially Ow	respond control r	unless the		d SEC 147	74 (9-02)
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)		4. Transaction Code		5. Number of Derivative Securities		(Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock Option				A		15,000		<u>(1)</u>	05/28/2020	Commo	n 15,000	\$ 0	15,000	D	

Reporting Owners

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
MOOS WALTER H C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94025-3493	X						

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/28/2010
-*Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.